<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01429818</url>
  </required_header>
  <id_info>
    <org_study_id>PET-GLI01</org_study_id>
    <nct_id>NCT01429818</nct_id>
  </id_info>
  <brief_title>Endothelial Disfunction Treatment With Glimepiride/Metformin Combination (Glimetal) in Type 2 Diabetes Patients</brief_title>
  <official_title>Endothelial Disfunction Treatment With Glimepiride/Metformin Combination (Glimetal) in Type 2 Diabetes Patients. Positron Emission Tomography Assessment(PET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Silanes S.A. de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Silanes S.A. de C.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of this study was to evaluate the effect of the combination glimepiride/metformin
      over endothelial dysfunction (ED) in asymptomatic patients with type 2 diabetes mellitus (DM)
      using 13N-ammonia-positron emission tomography (PET).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EDVI</measure>
    <time_frame>8 weeks</time_frame>
    <description>endothelial-dependent vasodilation index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MFR</measure>
    <time_frame>8 weeks</time_frame>
    <description>myocardial flow reserve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>%ΔMBF</measure>
    <time_frame>8 weeks</time_frame>
    <description>percentage of the change between rest and CPT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Glimepiride/metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride/metformin</intervention_name>
    <description>4/1000 mg tablets once a day foe eight weeks</description>
    <arm_group_label>Glimepiride/metformin</arm_group_label>
    <other_name>GLIMETAL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>1000 mg tablets once daily for eight weeks</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>PREDIAL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both genders

          -  At least 18 years old

          -  Type 2 diabetes mellitus diagnosis

          -  Signed Informed Consent

        Exclusion Criteria:

          -  History of smoking, hypertension, dyslipidemia, ischemic heart disease or autoimmune
             rheumatic diseases

          -  Pregnancy or lactation

          -  History of abuse and/or substance dependence within 6 months preceding the survey.

          -  History of glimepiride or metformin allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge González, MD</last_name>
    <role>Study Director</role>
    <affiliation>Laboratorios Silanes S.A. de C.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unidad PET Ciclotrón. Facultad de Medicina. Universidad Nacional Autónoma de México</name>
      <address>
        <city>Mexico city</city>
        <state>Distrito Federal</state>
        <zip>04510</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2011</study_first_submitted>
  <study_first_submitted_qc>September 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2011</study_first_posted>
  <last_update_submitted>September 6, 2011</last_update_submitted>
  <last_update_submitted_qc>September 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endothelial dysfunction</keyword>
  <keyword>Diabetes mellitus</keyword>
  <keyword>glimepiride</keyword>
  <keyword>metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

